Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View
Zacks Investment Research | Apr 27, 2017 02:42AM ET
Alexion Pharmaceuticals, Inc.’s (NASDAQ:ALXN) first-quarter 2017 earnings (including stock-based compensation expense) of $1.20 per share compared with the year ago earnings of 76 cents. The reported figure surpassed the Zacks Consensus Estimate of $1.05.
Revenues rose 24.1% year over year to $870 million, exceeding the Zacks Consensus Estimate of $821 million. The impact of currency headwind on the top line was 2% ($12 million).
Revenues in the quarter benefitted from an accounting change in revenue recognition. However, despite this benefit, total revenues rose 20%.
Shares of Alexion were up more than 4% in pre-market trading, in response to the better-than expected results. Alexion’s share price decreased 1.4% year to date, against the Zacks classified Medical - Biomedical and Genetics industry’s gain of 4.8%.
Revenue in Detail
Soliris sales were up 17.7% to $783 million during the quarter. Sales included a benefit of $29 million from the accounting change in revenue recognition.
While Strensiq contributed $74 million, up 124.2% year over year, Kanuma contributed $12 million, up considerably by 500% to quarterly revenues.
2017 Guidance
The company maintained its revenue guidance while raised its earnings guidance for 2017. The company expects adjusted earnings per share to be in the range of $5.10 to $5.30 up from its previously guidance range of $5.00 to $5.25. It projects revenues to be in the band of $3.4 to $3.5 billion same as the previous expectations. In fact, revenues for Soliris are maintained in the range of $3.03 to $3.1 billion.
Pipeline Update
The company continues to progress with the candidates in its pipeline. Alexion filed regulatory submissions for Soliris to treat patients with refractory generalized myasthenia in both the U.S. and Europe in Jan 2017. The applications have been accepted for review by the FDA and validated by the European Medicines Agency (EMA).
Alexion is evaluating Soliris in a couple of phase III studies – PREVENT, for the treatment of relapsing neuromyelitis optica spectrum disorder and expects to complete enrollment in this study this year.
Our Take
Alexion exceeded both earnings and revenue estimates in the first quarter and also raised its earnings guidance. We expect growth at Alexion to continue being driven by Soliris. Other new products – Strensiq and Kanuma – are doing well and should boost revenues. Eventually, reducing the company’s dependence on Soliris for growth. We are also impressed by Alexion’s efforts to develop its pipeline.
Get The News You Want
Alexion Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Alexion Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Alexion currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include Heska Corp. (NASDAQ:HSKA) , Galena Biopharma, Inc. (NASDAQ:GALE) and Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) sporting a Zacks Rank #1 (Strong Buy). You can see .
Heska’s earnings per share estimates increased from $1.53 to $1.65 for 2017 and from $1.80 to $2.01 for 2018, over the last 60 days. The company posted positive surprises in three of the four trailing quarters with an average beat of 291.54%. Its share price increased 50.7% year to date.
Galena’s loss per share estimates narrowed from $2.03 to 58 cents for 2017 over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters, with an average beat of 53.83%.
Infinity Pharma’s loss per share estimates narrowed from $1.10 to $1.03 for 2017 over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with an average beat of 36.64%.
Just Released – Driverless Cars: Your Roadmap to Mega-Profits Today
In this latest Special Report, Zacks’ Aggressive Growth Strategist Brian Bolan explores a full-blown technological breakthrough in the making – autonomous cars. He also spotlights 8 stocks with tremendous gain potential to feed off this phenomenon. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.